子宫内膜癌的检测与管理新策略。
New Strategies for Endometrial Cancer Detection and Management.
机构信息
Research, Innovation and HTA Unit, A.Li.Sa., Liguria Health Authority, 16121 Genoa, Italy.
出版信息
Int J Mol Sci. 2023 Mar 30;24(7):6462. doi: 10.3390/ijms24076462.
Abstract
With 400,000 new cases and over 80,000 deaths a year worldwide, endometrial cancer (EC) holds a rather unfortunate record, namely, that of the tumour with the highest increase in incidence, a unique trend among gynaecological cancers [...].
摘要
全世界每年有 40 万新发病例和超过 8 万人死亡，子宫内膜癌（EC）的记录相当不幸，即发病率增长最高的肿瘤，这在妇科癌症中是独一无二的趋势[...]。
相似文献
1
New Strategies for Endometrial Cancer Detection and Management.子宫内膜癌的检测与管理新策略。
Int J Mol Sci. 2023 Mar 30;24(7):6462. doi: 10.3390/ijms24076462.
2
Reflection on the current status of endometrial cancer in New Zealand.新西兰子宫内膜癌现状反思
Aust N Z J Obstet Gynaecol. 2019 Dec;59(6):874-876. doi: 10.1111/ajo.13057. Epub 2019 Sep 12.
3
ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma.ESGO/ESTRO/ESP 子宫内膜癌管理指南。
Int J Gynecol Cancer. 2021 Jan;31(1):12-39. doi: 10.1136/ijgc-2020-002230. Epub 2020 Dec 18.
4
The impact of histological subtype in developing both ovarian and endometrial cancer: A longstanding nationwide incidence study.组织学亚型在卵巢癌和子宫内膜癌发生发展中的影响：一项长期的全国性发病率研究。
Eur J Obstet Gynecol Reprod Biol. 2018 Feb;221:17-22. doi: 10.1016/j.ejogrb.2017.12.014. Epub 2017 Dec 7.
5
Do postmenopausal women with thickened endometrium on trans-vaginal ultrasound in the absence of vaginal bleeding need hysteroscopic assessment? A Pilot Study.经阴道超声检查显示子宫内膜增厚但无阴道出血的绝经后女性是否需要进行宫腔镜评估？一项初步研究。
J Obstet Gynaecol. 2016;36(2):223-6. doi: 10.3109/01443615.2015.1050649. Epub 2015 Oct 14.
6
Endometrial atypical hyperplasia and subsequent diagnosis of endometrial cancer: a retrospective audit and literature review.子宫内膜非典型增生及后续子宫内膜癌诊断：一项回顾性审计与文献综述
J Obstet Gynaecol. 2008 Aug;28(6):632-3. doi: 10.1080/01443610802355817.
7
Risk factors for developing endometrial cancer after benign endometrial sampling.良性子宫内膜取样后发生子宫内膜癌的风险因素。
Obstet Gynecol. 2013 Feb;121(2 Pt 1):381-382. doi: 10.1097/AOG.0b013e318280a16a.
8
Cancer of the endometrium.子宫内膜癌
Br J Cancer. 2001 May;84 Suppl 2(Suppl 2):31-6. doi: 10.1054/bjoc.2000.1760.
9
[Double and triple neoplasms in endometrial carcinoma].[子宫内膜癌中的双重和三重肿瘤]
Zentralbl Gynakol. 1994;116(9):522-6.
10
[Circulating tumor DNA assessment for gynaecological cancers management].用于妇科癌症管理的循环肿瘤DNA评估
Bull Cancer. 2019 Mar;106(3):237-252. doi: 10.1016/j.bulcan.2018.11.018. Epub 2019 Feb 11.
引用本文的文献
1
Combining demographic data and transvaginal ultrasonography: a predictive model for endometrial carcinoma in postmenopausal patients.结合人口统计学数据和经阴道超声：绝经后患者子宫内膜癌的预测模型。
BMC Womens Health. 2024 Sep 27;24(1):539. doi: 10.1186/s12905-024-03374-8.
2
Mechanism of regulation of KIF23 on endometrial cancer cell growth and apoptosis.KIF23对子宫内膜癌细胞生长和凋亡的调控机制。
Discov Oncol. 2024 Mar 21;15(1):83. doi: 10.1007/s12672-024-00937-x.
本文引用的文献
1
Identification of Diagnostic Biomarkers and Drug Targets for Endometrial Cancer-An Integrated in Silico Approach.子宫内膜癌诊断生物标志物和药物靶点的鉴定——一种综合的计算机方法。
Int J Mol Sci. 2022 Nov 18;23(22):14285. doi: 10.3390/ijms232214285.
2
TCGA Molecular Prognostic Groups of Endometrial Carcinoma: Current Knowledge and Future Perspectives.TCGA 子宫内膜癌分子预后分组：当前认识与未来展望。
Int J Mol Sci. 2022 Oct 2;23(19):11684. doi: 10.3390/ijms231911684.
3
Vibrational Biospectroscopy: An Alternative Approach to Endometrial Cancer Diagnosis and Screening.振动生物光谱学：子宫内膜癌诊断和筛查的另一种方法。
Int J Mol Sci. 2022 Apr 27;23(9):4859. doi: 10.3390/ijms23094859.
4
Sera Protein Signatures of Endometrial Cancer Lymph Node Metastases.子宫内膜癌淋巴结转移的血清蛋白特征。
Int J Mol Sci. 2022 Mar 18;23(6):3277. doi: 10.3390/ijms23063277.
5
Gel-Based Proteomic Identification of Suprabasin as a Potential New Candidate Biomarker in Endometrial Cancer.基于凝胶的蛋白质组学鉴定超结合珠蛋白作为子宫内膜癌潜在的新候选生物标志物。
Int J Mol Sci. 2022 Feb 14;23(4):2076. doi: 10.3390/ijms23042076.
6
Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) or proficient/stable (MMRp/MSS) endometrial cancer: interim results from GARNET-a phase I, single-arm study.多塔利单抗治疗晚期或复发性 DNA 错配修复缺陷/微卫星不稳定高（dMMR/MSI-H）或 proficient/stable（MMRp/MSS）子宫内膜癌患者的安全性和抗肿瘤活性：GARNET 研究的初步结果，一项 I 期单臂研究。
J Immunother Cancer. 2022 Jan;10(1). doi: 10.1136/jitc-2021-003777.
7
Clinical activity and safety of the anti-PD-1 monoclonal antibody dostarlimab for patients with recurrent or advanced dMMR endometrial cancer.抗 PD-1 单克隆抗体 dostarlimab 治疗复发性或晚期错配修复缺陷型子宫内膜癌患者的临床活性和安全性。
Future Oncol. 2021 Oct 1;17(29):3781-3785. doi: 10.2217/fon-2021-0598. Epub 2021 Aug 24.
8
New Insights into Endometrial Cancer.子宫内膜癌的新见解
Cancers (Basel). 2021 Mar 24;13(7):1496. doi: 10.3390/cancers13071496.
9
Aromatase Inhibitors as Adjuvant Treatment for ER/PgR Positive Stage I Endometrial Carcinoma: A Retrospective Cohort Study.芳香酶抑制剂作为 ER/PgR 阳性Ⅰ期子宫内膜癌的辅助治疗：一项回顾性队列研究。
Int J Mol Sci. 2020 Mar 23;21(6):2227. doi: 10.3390/ijms21062227.
Zotero 插件